An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00811564

Recruitment Status : Completed

First Posted : December 19, 2008

Results First Posted : September 21, 2011

Last Update Posted : September 21, 2011

Sponsor:

Information provided by:

Allergan

Study Description

Brief Summary:

A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects

Condition or disease	Intervention/treatment	Phase
Glaucoma Ocular Hypertension	Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution Drug: latanoprost 0.005%	Phase 4

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	148 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Investigator)
Primary Purpose:	Treatment
Study Start Date :	December 2008
Actual Primary Completion Date :	January 2010
Actual Study Completion Date :	January 2010

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Early-onset glaucoma Hypertension

MedlinePlus related topics: Glaucoma

Drug Information available for: Timolol Timolol maleate Brimonidine Brimonidine tartrate Latanoprost

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1 Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution	Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day Other Name: Combigan™
Active Comparator: 2 Latanoprost 0.005% ophthalmic solution	Drug: latanoprost 0.005% 1 drop of study medication taken once daily Other Name: Xalatan™

Outcome Measures

Primary Outcome Measures :

Intraocular Pressure (IOP) at Week 12 [ Time Frame: Week 12 ]
Mean IOP at week 12. IOP is a measurement of the fluid pressure inside the eye.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Be at least 18 years of age;
Give written informed consent;
Be in good general health as determined by your doctor;
Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension;
If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills);
Understand the study instructions, and be able to follow the study instructions; and
Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits.

Exclusion Criteria:

Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation;
Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and
Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Screening Visit

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811564

Locations

Layout table for location information

United States, New York

Slingerlands, New York, United States

Sponsors and Collaborators

Allergan

Investigators

Layout table for investigator information

Study Director:	Medical Director	Allergan

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Katz LJ, Rauchman SH, Cottingham AJ Jr, Simmons ST, Williams JM, Schiffman RM, Hollander DA. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Curr Med Res Opin. 2012 May;28(5):781-8. doi: 10.1185/03007995.2012.681036. Epub 2012 Apr 25.

Layout table for additonal information

Responsible Party:	Medical Affairs Director, Allergan, Inc.
ClinicalTrials.gov Identifier:	NCT00811564
Other Study ID Numbers:	GMA-COM-08-008
First Posted:	December 19, 2008 Key Record Dates
Results First Posted:	September 21, 2011
Last Update Posted:	September 21, 2011
Last Verified:	August 2011

Additional relevant MeSH terms:

Layout table for MeSH terms

Glaucoma Ocular Hypertension Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Timolol Brimonidine Tartrate Ophthalmic Solutions Latanoprost Pharmaceutical Solutions	Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists

To Top